Study identifier:5077/9038
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Randomised Double Blind, Placebo Controlled Study of Quetiapine Addition in OCD Patients Incompletely Responding to SSRIs
schizophrenia
Phase 3
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|